Financial Performance - Celldex Therapeutics reported a quarterly loss of $0.81 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.75, and compared to a loss of $0.56 per share a year ago, indicating a decline in performance [1] - The company posted revenues of $0.7 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 62.29%, while revenues a year ago were $0.16 million [2] - Over the last four quarters, Celldex has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Performance - Celldex shares have declined approximately 25.2% since the beginning of the year, contrasting with the S&P 500's decline of 4.3% [3] - The current Zacks Rank for Celldex is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.81 on revenues of $1.84 million, and for the current fiscal year, it is -$3.38 on revenues of $7.33 million [7] - The estimate revisions trend for Celldex is mixed, and future earnings expectations will depend on management's commentary during the earnings call [3][4] Industry Context - The Medical - Biomedical and Genetics industry, to which Celldex belongs, is currently in the top 33% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Celldex's stock performance [5]
Celldex Therapeutics (CLDX) Reports Q1 Loss, Lags Revenue Estimates